Clinical Proteomics in Diabetes and its Complications, July 20, 2007, Lister Hill Auditorium, Building 38A, NIH, Bethesda, MD
Clinical Proteomics in Diabetes and its Complications, July 20, 2007, Lister Hill Auditorium, Building 38A, NIH, Bethesda, MD
Home registration agenda Logistics Contact
Clinical Proteomics in Diabetes and its Complications, July 20, 2007, Lister Hill Auditorium, Building 38A, NIH, Bethesda, MD
Discussion Questions
  • Have the approaches used by the speakers been successful?
  • Based on the data presented, do you believe it may be possible to discriminate among people with diabetes, pre-diabetics, and normal individuals?
  • If the data indicate that it is possible to discriminate the diabetic condition, but not the pre-diabetic condition, is there a value in proceeding further by only analyzing samples from diabetics and normal individuals, and/or should we continue to analyze pre-diabetic samples?
  • Have the data presented provided sufficient preliminary data for moving forward by analyzing more samples?
  • Can the data presented from the various approaches be integrated and is there any advantage in doing so?
  • If the difference(s) between prediabetics and normal individuals and between prediabetics and people with diabetes are quantitative, is there already enough data from which to develop diagnostic cutoff values?
 
Clinical Proteomics in Diabetes and its Complications, July 20, 2007, Lister Hill Auditorium, Building 38A, NIH, Bethesda, MD
Department of Health and Human Services National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases